by Jason Heaviland | Mar 31, 2026 | Uncategorized
Researchers run experiments, send samples, and receive results that appear complete. However, a significant portion of the metabolome may never be captured in the final dataset. Not due to sample quality or preparation, but because many metabolomics platforms are...
by Jason Heaviland | Feb 26, 2026
This publication from SynDevRx examines the dual anti-obesity and anti-tumor effects of Evexomostat (SDX-7320), a METAP2 inhibitor evaluated in diet-induced obese mouse and rat models. Using Next-Generation Metabolomics from Panome Bio, the study reveals distinct...
by Jason Heaviland | Feb 26, 2026
Our partners at Indiana University leveraged Next-Generation Metabolomics to profile metabolic and lipidomic changes in gingival crevicular fluid from healthy individuals and patients with periodontitis. Using dual LC-MS platforms and deep-learning–assisted data...
by Jason Heaviland | Feb 25, 2026
Advancing Untargeted Metabolomics Data Analysis with MassID™ MassID™ is Panome Bio’s identification engine for Next-Generation Metabolomics®, designed to turn complex untargeted metabolomics data into confident metabolite identifications. By evaluating detected...
by Jason Heaviland | Feb 24, 2026
MassID™ Turning Untargeted Data into Confident Discoveries Get a quick overview of how MassID enhances Panome Bio’s true untargeted metabolomics by transforming raw LC-MS/MS data into high-confidence, biologically interpretable metabolite profiles using advanced,...
